-
Despite some limitations of trial design, including the open label nature of the study, RECORD remains the only randomized trial of cardiovascular outcomes for Avandia at this time.
FORBES: Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia
-
The content of his proposed topics is expected to be covered by other speakers as agency staff plan to summarize the available data on the cardiovascular safety of rosiglitazone at the committee meeting, and multiple FDA speakers will address their review of the readjudication of RECORD trial based on the study reports submitted to the Agency.
FORBES: The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meeting
-
So far, the joint effort between the Department of Justice and the Securities and Exchange Commission has produced nearly 70 guilty verdicts, a perfect record of convictions in criminal cases that have gone to trial, and millions of dollars in penalties.
FORBES: The Top Court Cases Of 2012